A
Amelia R. Ginardi
Researcher at Mayo Clinic
Publications - 4
Citations - 291
Amelia R. Ginardi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cytotoxic T cell & Antigen. The author has an hindex of 4, co-authored 4 publications receiving 285 citations.
Papers
More filters
Journal ArticleDOI
Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred
Pinku Mukherjee,Amelia R. Ginardi,Cathy S. Madsen,Christopher J. Sterner,Melissa C Adriance,Mary J. Tevethia,Sandra J. Gendler +6 more
TL;DR: The MET mice appropriately mimic the human condition and are an excellent model with which to elucidate the native immune responses that develop during tumor progression and to develop effective antitumor vaccine strategies.
Journal ArticleDOI
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Pinku Mukherjee,Cathy S. Madsen,Amelia R. Ginardi,Teresa L. Tinder,Fred Jacobs,Joanne Parker,Babita Agrawal,B. Michael Longenecker,Sandra J. Gendler +8 more
TL;DR: Using an injectable breast cancer model, the authors show that targeting a single tumor antigen may not be an effective antitumor treatment, but that immunization with dendritic cells fed with whole tumor lysate is effective in breaking tolerance and protecting mice from subsequent tumor challenge.
Journal ArticleDOI
MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Pinku Mukherjee,Amelia R. Ginardi,Cathy S. Madsen,Teresa L. Tinder,Fred Jacobs,Joanne Parker,Babita Agrawal,B. Michael Longenecker,Sandra J. Gendler +8 more
TL;DR: It is demonstrated that the CTL tolerance could be reversed at least in vitro with the use of anti-CD40 co-stimulation, which indicates theuse of several immune evasion mechanisms by tumor cells to evade CTL killing.
Journal Article
MUC1-specific Cytotoxic T Lymphocytes Eradicate Tumors When Adoptively Transferred in Vivo
TL;DR: The first evidence that demonstrates that the naturally occurring Muc1-specific CTLs isolated from one tumor model has antitumor effects on other MUC1-expressing tumors in vivo is demonstrated, which confirms that M UC1 is an important tumor rejection antigen and can serve as a target for immunotherapy.